PolyPid(PYPD) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For Q4 2025, research and development expenses decreased to $6.2 million from $7 million in Q4 2024, reflecting the completion of the SHIELD II Phase III trial [14] - General and administrative expenses increased to $1.8 million in Q4 2025 from $1 million in Q4 2024, primarily due to non-cash expenses related to performance-based options [15] - The net loss for Q4 2025 was $8.5 million or $0.41 per share, unchanged from the net loss of $8.5 million or $1.13 per share in Q4 2024 [15] - For the full year 2025, net loss was $34.2 million or $2.09 per share, compared to a net loss of $29 million or $4.91 per share in 2024 [16] Business Line Data and Key Metrics Changes - The company successfully completed the SHIELD II Phase III trial, with D-PLEX100 meeting its primary and key secondary endpoints [6] - The company is advancing its long-acting GLP-1 receptor agonist program alongside D-PLEX100 [6] Market Data and Key Metrics Changes - The company received positive feedback from the FDA regarding the regulatory pathway for D-PLEX100, supporting a rolling NDA submission expected to begin by the end of Q1 2026 [7] - The company is in advanced stages of partnership discussions in the U.S., reflecting recognition of D-PLEX100's strong clinical profile [8] Company Strategy and Development Direction - The company is transitioning from a primarily R&D-focused organization to one preparing for commercialization, with a focus on regulatory pathways and commercial partnerships [6][10] - The introduction of Kynatrix technology represents an expansion of the company's capabilities beyond localized delivery, targeting systemic therapeutic needs [13] Management's Comments on Operating Environment and Future Outlook - Management believes 2026 could be a transformative year, with the rolling NDA submission and ongoing partnership discussions [9] - The company is preparing for market approval and launch, emphasizing the importance of building awareness and readiness among stakeholders [30] Other Important Information - The company appointed Ms. Brooke Story as chairman of the board in December 2025, bringing extensive experience in medical technology [9] Q&A Session All Questions and Answers Question: Can you share how discussions around the scope of the label progressed? - The company is targeting an initial label for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, supported by Phase III data [21] Question: Any thoughts on plans for a broader label or further expansion opportunities for D-PLEX100? - The company plans to meet with the FDA to discuss potential label expansion opportunities during the review process [23] Question: What work is being done to prepare for potential approval of D-PLEX100? - The company is focusing on market research, building awareness, and creating a KOL network to prepare for commercialization [31] Question: How do you think about strategic partnerships for the GLP-1 program? - The company aims to partner at an early stage, leveraging robust preclinical data to attract interest from potential partners [34] Question: What factors will play a role in identifying the final partner for D-PLEX100? - The ideal partner will have broad hospital-based capabilities and presence in the surgical suite, essential for marketing the product [40] Question: What percentage of potential target IDNs would likely include D-PLEX on formulary within the first 12 months after approval? - The uptake will take time, with a few months before seeing meaningful updates, but once on formulary, usage is expected to grow steadily [48]